Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5 microg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20 microg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.

Trial Profile

Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5 microg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20 microg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Ipratropium bromide; Theophylline
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms SECURE 2
  • Sponsors AstraZeneca

Most Recent Events

  • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 04 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 20 Sep 2011 Additional trial location (China) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top